News in the Life Sciences Industry

BERGEN, Norway, Sept. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib... Read more ››

100th Leksell Gamma Knife Icon begins operations at Kaunos Klinikos

STOCKHOLM, Sept. 5, 2019 /PRNewswire/ -- Stefan Grass with extensive clinical experience as a physician and researcher, combined with senior positions in the pharmaceutical industry, has been recruited to a newly established, global role as Chief Medical and Technology Officer. He will assume... Read more ››

STOCKHOLM, Sept. 5, 2019 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August 30, 2019.

STOCKHOLM, Sept. 5, 2019 /PRNewswire/ -- Heidelberg University Hospital, Germany, has treated its first patient using Monte Carlo photon dose planning in RayStation®*. The decision to go clinical was made after a thorough validation of the functionality. The first patient, who has cervical... Read more ››

STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod. An orphan drug... Read more ››

STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Bioservo Technologies AB (publ) (Nasdaq First North: BIOS) has entered an exclusive distribution agreement for selling the all-new Ironhand® with ITURRI, SA. Group for the German, Spanish, Portuguese and Polish market. ITURRI has a management team... Read more ››

STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Preliminary results show that Enzymatica's prospective, randomized, double-blinded multicenter study did not meet the primary end-point "Significant improvement of quality of life during treatment with ColdZyme compared to placebo in common cold".... Read more ››

STOCKHOLM, Sept. 4, 2019 /PRNewswire/ -- Cantargia AB today announced that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the current documentation on the antibody CAN04 and a proposed new phase I clinical combination study with... Read more ››

OSLO, Norway, Sept. 4, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that its CEO, Eduardo Bravo, will participate and present at the following upcoming investor conferences during September: